The recent outbreak of coronavirus disease 2019 (COVID-19) by SARS-CoV-2 has led to uptodate 24.3 M cases and 0.8 M deaths. It is thus in urgent need to rationalize potential therapeutic targets against the progression of diseases. An effective, feasible way is to use the pre-existing ΔORF6 mutant of SARS-CoV as a surrogate for SARS-CoV-2, since both lack the moiety responsible for interferon antagonistic effects. By analyzing temporal profiles of upregulated genes in ΔORF6-infected Calu-3 cells, we prioritized 55 genes and 238 ligands to reposition currently available medications for COVID-19 therapy. Eight of them are already in clinical trials, including dexamethasone, ritonavir, baricitinib, tofacitinib, naproxen, budesonide, ciclesonide and formoterol. We also pinpointed 16 drug groups from the Anatomical Therapeutic Chemical classification system, with the potential to mitigate symptoms of SARS-CoV-2 infection and thus to be repositioned for COVID-19 therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817445 | PMC |
| http://dx.doi.org/10.1016/j.ygeno.2020.12.041 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A review of RNA nanoparticles for drug/gene/protein delivery in advanced therapies: Current state and future prospects.
Int J Biol Macromol
January 2025
Australasian Nanoscience and Nanotechnology Initiative (ANNI), Monash University LPO, Clayton, VIC 3168, Australia.
Nanotechnology involves the utilization of materials with exceptional properties at the nanoscale. Over the past few years, nanotechnologies have demonstrated significant potential in improving human health, particularly in medical treatments. The self-assembly characteristic of RNA is a highly effective method for designing and constructing nanostructures using a combination of biological, chemical, and physical techniques from different fields.
View Article and Find Full Text PDFHumoral immune response to SARS-CoV-2 vaccines in patients with autoimmune rheumatic diseases.
Arch Med Res
January 2025
Servicio de Reumatología, Hospital Angel Cruz Padilla, Tucumán, Argentina.
Background: Patients with autoimmune rheumatic diseases (ARD) are at increased risk of infection due to their impaired immune response, which also reduces vaccination efficacy. Although several studies have evaluated the serological response to SARS-CoV-2 mRNA-based vaccines in patients with ARD, limited information on immune responses to other vaccination platforms is available.
Aims: This observational prospective study aims to investigate the humoral immune response to different SARS-CoV-2 vaccines in patients with ARD.
"Thoracic anesthesia in patients with airborne disease".
Best Pract Res Clin Anaesthesiol
March 2024
Department of Surgery, Universitat de València, 46010 València, Spain; Ivano-Frankivsk National Medical University, 76018 Ivano-Frankivsk, Ukraine.
Health care workers are at risk of infection from aerosolization of respiratory secretions, droplet and contact spread. This has gained great importance after the COVID19 pandemic. Intra-operative aerosol-generating procedures are arguably unavoidable in the routine provision of thoracic anesthesia.
View Article and Find Full Text PDFExtracorporeal membrane oxygenation and pregnancy.
Best Pract Res Clin Anaesthesiol
September 2024
Department of Anaesthesiology, University Hospitals Leuven (BE), Department of Cardiovascular Sciences, KU Leuven (BE), Herestraat 49, B-3000, Leuven, Belgium.
Critical illness during pregnancy poses significant challenges driven by complex interactions between physiological changes, pre-existing conditions, and healthcare disparities. In high-income countries, increasing maternal age and comorbidities complicate obstetric care by triggering an unprecedented rise in cardiac disease during pregnancy, while infections like influenza and COVID-19 are important causes of maternal adult respiratory distress syndrome. Extracorporeal membrane oxygenation (ECMO) gained prominence as a vital intervention, providing respiratory and/or cardiac support, for varying indications between antenatal and postpartum periods.
View Article and Find Full Text PDFCan there be calm during a cytokine storm? Immune checkpoint pathways affecting the severity of COVID-19 disease.
Front Microbiol
December 2024
Department of Medical Microbiology and Immunology, Medical School, University of Pecs, Pecs, Hungary.
Introduction: The COVID-19 pandemic has become a global health crisis, eliciting varying severity in infected individuals. This study aimed to explore the immune profiles between moderate and severe COVID-19 patients experiencing a cytokine storm and their association with mortality. This study highlights the role of PD-1/PD-L1 and the TIGIT/CD226/CD155/CD112 pathways in COVID-19 patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!